

New Drug, Generic, and Biosimilar Pipeline Report

Q1 2024

What follows is a summary of significant predicted forthcoming drug launches over the next 12 months of newly approved brand drugs, generic drug drugs, and biosimilars.

New Drug Pipeline

GENERIC NAME	BRAND NAME (Manufacturer if drug name unavailable)	ROUTE OF ADMINISTRATION	STATUS	ESTIMATED COST	THERAPEUTIC AREA	SPECIALTY OR TRADITIONAL
Bimekizumab	Bimzelx	Subcutaneous	Launched Oct 2023	\$93,600 annually	Dermatology: Plaque Psoriasis	Specialty
Etrasimod	Velsipity	Oral	Launched Oct 2023	\$75,000 annually	Gastrointestinal: Ulcerative Colitis	Specialty
Treprostinil DPI	Yutrepia	Inhaled*	Jan 2024	TBD	Pulmonary Arterial Hypertension	Specialty
Scopolamine	(Repurposed Therapeutics/Defender Pharmaceuticals)	Nasal*	Jan 2024	TBD	Gastrointestinal: Motion Sickness	Traditional
Atropine Sulfate	(Nevakar/Vyluma)	Ophthalmic*	Jan 2024	\$5,000 annually	Ophthalmic: Myopia	Traditional
Roluperidone	(Mitsubishi Tanabe Minerva)	Oral	Feb 2024	\$20,000-\$30,000 annually	Central Nervous System: Schizophrenia	Traditional
Glatiramer Acetate	GA Depot	Intramuscular*	Mar 2024	TBD	Central Nervous System: Multiple Sclerosis	Specialty
Givinostat	Duvyzat	Oral	Mar 2024	\$350,000 annually	Central Nervous System: Duchenne Muscular Dystrophy	Specialty
Sotatercept	(Merck)	Subcutaneous	Mar 2024	\$300,000-\$500,000 annually	Pulmonary: Pulmonary Arterial Hypertension	Specialty
Aprocitentan	(Janssen)	Oral	Mar 2024	TBD	Cardiovascular: Hypertension	Specialty
Resmetirom	(Madrigal)	Oral	Mar 2024	\$20,000-\$50,000 annually	Endocrine: Metabolic Dysfunction associated Steatohepatitis (MASH)	Specialty
Vadadustat	Vafseo	Oral	Mar 2024	TBD	Hematological Agents: Chronic Kidney Disease	Specialty
Leqembi (self-administered)	(Biogen/Eisai)	Subcutaneous*	1Q2024	\$26,000 annually	Central Nervous System: Alzheimer's Disease	Specialty
Bulevirtide	Mycludex or Hepcludex	Subcutaneous	1Q2024	TBD	Anti-Infectives: Antivirals	Specialty

Drug Pipeline Report

GENERIC NAME	BRAND NAME (Manufacturer if drug name unavailable)	ROUTE OF ADMINISTRATION	STATUS	ESTIMATED COST	THERAPEUTIC AREA	SPECIALTY OR TRADITIONAL
Macitentan; Tadalafil STCT	(Janssen)	Oral	1Q2024	TBD	Pulmonary Arterial Hypertension	Specialty
Pivmecillinam	(LEO Pharma)	Oral	Apr 2024	TBD	Anti-Infectives: Antibiotics	Traditional
Mavoxifafor	(X4 Pharmaceuticals)	Oral	Apr 2024	\$100,000-\$200,000 annually	Autoimmune	Specialty
Diazepam	Libervant	Oral*	Apr 2024	TBD	Central Nervous System: Epilepsy	Specialty
Tovorafenib	(Day One Biopharmaceuticals/Takeda)	Oral	Apr 2024	\$250,000 annually	Cancer: Brain	Specialty
Palopegteriparatide	TransCon PTH	Subcutaneous	May 2024	\$100,000-\$300,000 annually	Endocrine: Hypoparathyroidism	Specialty
Rivoceranib	(Jiangsu Hengrui Medicine LSK BioPharma)	Oral	May 2024	TBD	Cancer: Gastrointestinal	Specialty
Elafibranor	(Genfit; Ipsen)	Oral	Jun 2024	TBD	Endocrine: Metabolic Dysfunction associated Steatohepatitis (MASH)	Specialty
Arimoclomol	Miplyffa	Oral	Jun 2024	TBD	Endocrine: Niemann-Pick disease Type C	Specialty
Ensifentrine	(Verona Pharma)	Inhaled	Jun 2024	\$18,000 annually	Respiratory: Asthma/COPD	Traditional
Sofdra	(Sofpironium Bromide)	Topical	Jun 2024	TBD	Dermatology: Hyperhidrosis	Traditional
Budesonide	Eohilia	Oral*	1H2024	TBD	Gastrointestinal: Eosinophilic Esophagitis	Specialty
Danicopan	(Alexion/AstraZeneca)	Oral	1H2024	\$100,000-\$200,000 annually	Hematologic: Paroxysmal nocturnal hemoglobinuria	Specialty
Follitropin Delta	Rekovelle	Subcutaneous*	1H2024	TBD	Endocrine: Infertility	Specialty
Naloxone	Orexo	Nasal*	Jul 2024	TBD	Addiction/Substance Abuse	Traditional
Crovalimab	(Roche/Chugai)	Intravenous/Subcutaneous	Jul 2024	\$300,000-\$500,000	Hematological: Paroxysmal Nocturnal Hemoglobinuria	Specialty
Galantamine Benzoate	(Alpha Cognition)	Oral	Jul 2024	TBD	Central Nervous System: Alzheimer's/Dementia	Traditional
Deuruxolitinib	(Concert/Sun)	Oral	Jul 2024	TBD	Dermatology: Alopecia Areata	Specialty
Vonoprazan	Voquezna (Phathom Pharmaceuticals)	Oral	Jul 2024	\$8,000 annually	Gastrointestinal: Non-erosive reflux disease (NERD)	Traditional
Insulin icodec	(Novo Nordisk)	Subcutaneous	2Q2024	\$5,000 annually	Endocrine: Diabetes	Traditional

Drug Pipeline Report

GENERIC NAME	BRAND NAME (Manufacturer if drug name unavailable)	ROUTE OF ADMINISTRATION	STATUS	ESTIMATED COST	THERAPEUTIC AREA	SPECIALTY OR TRADITIONAL
Tradipitant	(Vanda Pharmaceuticals)	Oral	Sept 2024	\$10,000-\$20,000 per course	Gastroenterology: Nausea	Specialty
Xanomeline; Trospium Chloride	KarXT	Oral	Sept 2024	\$20,000-\$30,000 annually	Central Nervous System: Schizophrenia	Traditional
Lebrikizumab	(Eli Lilly)	Subcutaneous	2H2024	\$50,000	Dermatology: Atopic Dermatitis	Specialty
Seladelpar	(CymaBay Therapeutics)	Oral	2H2024	\$110,000 annually	Gastrointestinal: Primary biliary cholangitis	Specialty
Midomafetamine (MDMA)	(MAPS PBC; Lykos Therapeutics)	Oral	2H2024	\$5,000-\$10,000 per course	Central Nervous System: Mood Disorders	Specialty
Govorestat	(Applied Therapeutics)	Oral	2H2024	TBD	Endocrine: Metabolic	Specialty
Revumenib	(Syndax)	Oral	2H2024	TBD	Cancer: Leukemia	Specialty
Glepaglutide	(Zeland Pharma)	Subcutaneous	4Q2024	\$540,000 annually	Gastrointestinal: Short Bowel Syndrome	Specialty
Lazertinib	YuHan	Oral	4Q2024	TBD	Cancer: Non-Small Cell Lung Cancer	Specialty
Vicagrel	(Jiangsu Vcare Pharmatech)	Oral	4Q2024	TBD	Cardiovascular: Acute Coronary Syndrome	Specialty
Acoramidis	(BridgeBio/Eidos Therapeutics)	Oral	4Q2024	\$200,000 - \$300,000 annually	Endocrine: Metabolic	Specialty
Reproxalap	(Aldeyra Therapeutics)	Topical: Ophthalmic	4Q2024	TBD	Ophthalmology: Dry Eye Disease	Traditional

Generic and Biosimilar Pipeline

RUG NAME	BRAND NAME	ROUTE OF ADMINISTRATION	STATUS	ESTIMATED 2022 US SALES (MILLIONS)	THERAPEUTIC AREA	BIOSIMILAR OR TRADITIONAL
Pitavastatin	Livalo	Oral	Launched Nov 2023	\$345	Cardiology	Traditional
Gabapentin	Gralise	Oral	Jan 2024	\$100	Central Nervous System	Traditional
Nilotinib	Tasigna	Oral	Jan 2024	\$2,200	Cancer: Leukemia	Biosimilar
Deflazacort	Emflaza	Oral	Feb 2024	\$300	Musculoskeletal: Duchenne Muscular Dystrophy	Biosimilar
Zymfentra (Infliximab)	Remicade*	Subcutaneous	Feb 2024	\$6,137	Anti-Inflammatory	Biosimilar
Lamivudine/Raltegravir	Dutrebis	Oral	Mar 2024	N/A	Anti-Infectives: HIV	Traditional
Risperidone	Risvan	Intramuscular	Mar 2024	\$15,000-\$35,000/year	Central Nervous System: Antipsychotic	Traditional
Insulin Glargine	Lantus	Subcutaneous	1Q2024	\$11,755	Endocrine: Diabetes	Traditional

Drug Pipeline Report

RUG NAME	BRAND NAME	ROUTE OF ADMINISTRATION	STATUS	ESTIMATED 2022 US SALES (MILLIONS)	THERAPEUTIC AREA	BIOSIMILAR OR TRADITIONAL
Zercepac (Trastuzumab)	Herceptin	Intravenous	1Q2024	\$752	Cancer: Breast	Biosimilar
Rapilin (Insulin Aspart)	Novolog	Subcutaneous	Apr 2024	\$6,532	Endocrine: Diabetes	Traditional
Prandilin (Insulin Lispro)	Humalog	Subcutaneous	Apr 2024	\$5,520	Endocrine: Diabetes	Traditional
Xlucane (Ranibizumab)	Lucentis	Intravitreal*	Apr 2024	\$1,920	Ophthalmic: Macular Degeneration	Biosimilar
Edaravone	Radicava	Intravenous	May 2024	\$330	Central Nervous System: ALS	Biosimilar
Aflibercept	Eylea	Intravitreal	Jun 2024	\$6,795	Ophthalmic: Macular Degeneration	Biosimilar
Liraglutide	Victoza	Subcutaneous	Jun 2024	\$3,700	Endocrine: Diabetes	Traditional
Rituximab	Rituxan	Intravenous*	2Q2024	\$2,035	Anti-Inflammatory	Biosimilar
Tyruko (Natalizumab)	Tysabri	Intravenous*	1H2024	\$1,783	Central Nervous System: Multiple Sclerosis	Biosimilar
Ryzneuta (Efbemalenograstim Alfa-vuxw)	Neulasta	Subcutaneous*	1H2024	\$1,006	Cancer	Biosimilar
Filgrastim	Neupogen	Intravenous/Subcutaneous*	1H2024	\$167	Hematological Agents	Biosimilar
Dasatinib	Sprycel	Oral	Sept 2024	\$2,000	Cancer	Biosimilar
Oxcarbazepine	Oxtellar XR	Oral	Sept 2024	\$230	Central Nervous System: Epilepsy	Traditional
Teduglutide	Gattex	Subcutaneous	2024	\$180	Gastrointestinal	Biosimilar
Raltegravir	Isentress	Oral	2024	\$320	Anti-Infectives: HIV	Traditional
Denosumab	Prolia	Subcutaneous	2024-2025	\$3,218	Cancer	Biosimilar
Toclizumab (Tyenne)	Actemra	Intravenous*	2024-2025	\$864	Anti-Inflammator	Biosimilar
Ustekinumab	Stelara	Subcutaneous	Jan 2025	\$18,086	Anti-Inflammatory	Biosimilar
Formoterol/Mometasone	Dulera	Inhaled	TBD	\$500	Respiratory	Traditional

Nothing herein is or shall be construed as a promise or representation regarding past or future events and Serve You Rx expressly disclaims any and all liability relating to the use or reliance on the information contained in this publication. The information contained in this publication is intended for educational purposes only and should not be considered clinical, financial, or legal advice. By receipt of this publication, each recipient agrees that the information contained herein will be kept confidential and that the information will not be photocopied, reproduced, distributed to, or disclosed to others at any time without the prior written consent of Serve You Rx.

*New Formulation of an Existing Product

Source: IPD Analytics, 2024